Previously submitted to: Interactive Journal of Medical Research (no longer under consideration since Apr 29, 2025)
Date Submitted: Aug 3, 2022
Open Peer Review Period: Aug 3, 2022 - Sep 28, 2022
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Telemonitoring patients with COPD: a scope literature review.
ABSTRACT
Background:
Telemonitoring projects involving patients with pulmonary conditions have demonstrated the ability to identify early changes in the condition of patients. There is little consensus about the benefits of home telemonitoring on pulmonary conditions.
Objective:
to review the benefits and cost-effectiveness of telemonitoring on patients with COPD.
Methods:
We performed a scope literature review on PubMed and Google Schoolar and selected articles according with Prisma Statement 2020 checklist criteria. Population were defined as equal or above 18 years-old with confirmed diagnosis of COPD; intervention was defined as the implementation of a telemonitoring system at home; comparison was defined as intervention group will be compared with a group of patients diagnosed with COPD, without home telemonitoring. Primary outcomes were cost-effectiveness of telemonitoring and admissions fee to the emergency department for COPD.
Results:
We identified a total of 27.443 articles and we analyzed a total of 708 articles. We included a total of 13 articles in this review after applying PICO, inclusion and exclusion criteria. Differences were found on COPD and telemonitoring definitions. Results indicate that home telemonitoring can reduce the risk hospital admissions and improve cost-effectiveness, as more severe patients may benefit more from telemonitoring.
Conclusions:
Reducing exacerbations, admission on emergency departments and improve cost-effectiveness are major goals for home telemonitoring on COPD patients. Despite the benefits, another important conclusion is that more studies are needed in order to sustain more the use of home telemonitoring.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.